PGR and invasive carcinoma: The College of American Pathologists and the American Society of Clinical Oncology have recommended the evaluation of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu receptor for all newly diagnosed cases of invasive carcinoma [4].